Gallbladder Cancer
Intravenous exatecan administered daily to patients with biliary tract cancers
Published in Vaccine Weekly, October 12th, 2005
"Exatecan is a hexacyclic topoisomerase-1 inhibitor that has broad in vitro and in vivo activity. A multicenter phase II study to determine the antitumor activity of exatecan was conducted in patients with advanced cholangiocarcinoma and gallbladder carcinoma. Patients with 0 to 1 prior chemotherapy regimens, adequate major organ function, and metastatic disease were eligible," scientists reported in the American Journal of Clinical Oncology - Cancer Clinical Trials.
"Exatecan was administered at a dose of .5 mg/m2 IV over 30...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2005-10-12)
More Articles from Vaccine Weekly
- Hepatitis C Vaccine Development
Hepatitis C virus-host interactions examined - Myeloma Vaccine Development
Tumor antigen immunization of stem cell transplant donors reported - Rotavirus Vaccine Development
Human rotavirus-bovine rotavirus reassortant vaccine developed - Rotavirus Vaccine Development
Pentavalent rotavirus vaccine against gastroenteritis developed - Vaccine Development
Killed but active microbes proposed for new vaccine paradigm - Anthrax Vaccine Development
Antibody patterns in anthrax vaccinees reported - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
